PAK4
Serine/threonine-protein kinase PAK 4
As of the edition of 20 October 2026, PAK4 (serine/threonine-protein kinase PAK 4, UniProt O96013) has 2 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O96013
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 50
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue
- Registered trials of its drugs
- 3
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Padnarsertib | Stopped | Phase 1 | none listed |
| PF-03758309 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Karyopharm Therapeutics | Route A |
| Antengene | Route A |
The other 0 companies at PAK4
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at PAK4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.